ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona
Biotech companies at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
72 biotech companies are at ESMO 2026 — 51 presentations on the program and 37 with a booth in the exhibit hall. Most represented: XYone Therapeutics (2 on the program), iNtRON Biotechnology (2 on the program), Calidi Biotherapeutics (2 on the program). 40 of them have their own page in this guide. As of Nov 2, 2026.
Tumour type
Top represented
Showing 1–14 of 72 organizations
| Organization | ESMO 2026 Attendance |
|---|---|
XT XYone Therapeutics Canton, MA | |
Oncology drug developer studying antibody–drug conjugates for cancer treatment. | Poster Fri Oct 23 13:00–15:00 MUC1-C Targeting ADC Exhibits Potent Anti-tumor Activity in KRAS-mutant Gastric Adenocarcinoma Gastrointestinal cancers Poster Fri Oct 23 15:15–16:00 Targeting MUC1 in advanced genitourinary malignancies: Expression landscape, molecular correlates, and preclinical activity of novel antibody-drug conjugates in prostate and bladder cancers Genitourinary cancersBiomarkers & precision oncology Poster Mon Oct 26 12:00–12:45 |
South Korean biotech developing bacteriophage and endolysin-based medicines, including phage-derived candidates for colorectal cancer. | Booth Exhibiting at Booth 1102 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 |
Calidi Biotherapeutics San Diego, CA | |
Biotechnology company developing cell and viral therapies for cancer. | Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 |
M mAbxience Madrid, Spain | |
Biotechnology company developing and manufacturing biosimilar medicines. | Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 LEON study: A PK-driven biosimilarity study of MB11 to nivolumab in advanced melanoma Melanoma & skin cancers |
HB HighField Biopharmaceuticals Hangzhou, China | |
Biopharmaceutical company developing cancer therapies in Hangzhou, China. | Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 |
SP STCube Pharmaceuticals Rockville, MD | |
Biotechnology company developing cancer therapeutics. | Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Cell DIVE profiling of BTN1A1-associated spatial TME phenotypes in refractory CRC Gastrointestinal cancers |
Spanish biopharmaceutical company developing and marketing marine-derived cancer medicines, including trabectedin and lurbinectedin. | Booth Exhibiting at Booth 1066 Poster Fri Oct 23 13:00–15:00 Satellite Sat Oct 24 18:30–20:00 PharmaMar - More time for patients: Reframing the course of ES-SCLC Lung & thoracic cancers |
Actinium Pharmaceuticals New York, NY | |
A biotechnology company developing targeted radiotherapies for cancer. | Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 |
BioNTech Mainz, Germany | |
German biotech developing mRNA cancer immunotherapies, antibody-drug conjugates and bispecific antibodies. | Booth Exhibiting at Booth 8070 Poster Fri Oct 23 15:15–16:00 |
US biotech developing targeted cancer therapies, including antibody-drug conjugates and a gamma secretase inhibitor for desmoid tumours. | Booth Exhibiting at Booth 8017 Poster Mon Oct 26 12:00–12:45 Exposure-response (ER) analyses to support the recommended dose of varegacestat (VAR) for patients (pts) with desmoid tumors (DT) Sarcoma, CNS, head & neck and rare cancers |
Clinical-stage oncology company developing treatments against cancer resistance mechanisms, with programs in prostate and lung cancer. | Booth Exhibiting at Booth 8103 |
AIDA Oncology Copenhagen, Denmark | |
Oncology biotechnology company developing RNA-based tools to predict treatment response and help clinicians select cancer therapies. | Poster Sun Oct 25 12:00–12:45 Prediction of ADC pay-load: TOP1 predictor development Breast cancerBiomarkers & precision oncology |
A9 Alpha-9 Oncology Boston, MA | |
Oncology drug developer studying radioligand therapies for cancer. | Poster Fri Oct 23 13:00–15:00 A phase 1/1b study of GRPR-targeted radioligand therapy with [177Lu] Lu-A9-0631 and [225Ac] Ac-A9-0642 in patients with GRPR-positive solid tumors Gastrointestinal cancersBreast cancerGenitourinary cancers |
A Alteogen Daejeon, Republic of Korea | |
Biotechnology company developing medicines, including antibody-drug conjugate technologies. | Poster Fri Oct 23 13:00–15:00 Berahyaluronidase alfa enables subcutaneous administration of antibody–drug conjugates with improved local and hematologic tolerability Haematological malignanciesBreast cancerMelanoma & skin cancersSarcoma, CNS, head & neck and rare cancers |
Find buyers from biotech companies
Tell us what you sell and we’ll find the people at these biotech companies most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Browse ESMO 2026 by
Organization type
Tumour type
Exhibit hall
Everyone
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction